RecruitingPhase 1NCT06846606

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

A Phase 1 Study of AUTX-703 in Participants With Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

Sponsor

Auron Therapeutics, Inc.

Enrollment

69 participants

Start Date

May 1, 2025

Study Type

INTERVENTIONAL

Conditions

Relapsed / refractory AML Refractory Acute Myeloid Leukemia (AML)Relapsed Acute Myeloid Leukemia (AML)Relapsed Myelodysplastic Syndromes Refractory Myelodysplastic Syndromes Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Summary

This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of AUTX-703 administered orally in subjects with advanced hematologic malignancies.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AUTX-703 for people with refractory acute myeloid leukemia (aml), refractory myelodysplastic syndromes, and other related conditions. The study is currently recruiting participants at 9 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAUTX-703

AUTX-703 administered orally

Locations(9)

City of Hope National Medical Center

Duarte, California, United States

H Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, United States

Roswell Park Comprehensive Cancer Center

Buffalo, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States

Ohio State University, The James Comprehensive Cancer

Columbus, Ohio, United States

UPENN Perelman Center for Advanced Medicine

Philadelphia, Pennsylvania, United States

Sarah Cannon Center for Blood Cancer at TriStar Centennia

Nashville, Tennessee, United States

University of Texas MD Anderson Cancer Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06846606

Related Trials

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

NCT074718411 location

CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML

NCT073474181 location

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

NCT069500347 locations

A Randomised Phase III Study of Elacytarabine vs. Investigator’s Choice in Patients with Late Stage Acute Myeloid Leukaemia

ACTRN1261100047495412 locations